These findings suggest that the dual blockade of the PD-L1/PD-1 and PD-L2/PD-1 axes is important for enhancing the anti-tumor efficacy of HTL peptide vaccines against ROR1 in HNSCC. The gene discussed is PDCD1LG2; the disease is neoplasm.